Anumana and Pfizer partner for cardiovascular disease detection

Related Articles
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 20, 2022
Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024
Company to highlight how its ECG-AI® algorithms enable earlier cardiovascular disease detectionNovember 14, 2024
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022
Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it
Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to…April 13, 2021


